Given the resiliency of the healthcare sector in terms of economic uncertainty, I want to continue to expand my portfolio in this sector, particularly where I feel confident about the future growth years from now. This leads me to the world of biosimilars and Coherus Biosciences (NASDAQ: CHRS). Coherus has an interesting valuation profile, trading at 6x revenues and only 8x forward earnings before the coronavirus pandemic. This is due to a wide range of risks associated with future profitability. But even after accounting for those risks, Coherus looks to be undervalued today and will